Preferred Label : fluorenes;

MeSH definition : A family of diphenylenemethane derivatives.;

MeSH annotation : carcinogenic aromatic hydrocarbons; do not confuse with FLUORINE; D25-26 qualif; do not confuse with FLUORINE;

Is substance : O;

Details


Main resources

You can consult :

A family of diphenylenemethane derivatives.

https://www.has-sante.fr/jcms/p_3224404/fr/harvoni
2020
false
false
false
France
French
evaluation of the transparency committee
treatment outcome
insurance, health, reimbursement
administration, oral
ledipasvir, sofosbuvir drug combination
Product containing only ledipasvir and sofosbuvir in oral dose form (medicinal product form)
antiviral agents
hepatitis C, chronic
child
adolescent
adult
sofosbuvir and ledipasvir
benzimidazoles
fluorenes
uridine monophosphate
uridine monophosphate

---
https://www.has-sante.fr/jcms/p_3152635/fr/harvoni
2020
false
false
false
France
Sofosbuvir
treatment outcome
ledipasvir
ledipasvir, sofosbuvir drug combination
adult
adolescent
antiviral agents
drug combinations
hepatitis C, chronic
evaluation of the transparency committee
Harvoni
benzimidazoles
fluorenes
uridine monophosphate
uridine monophosphate

---
https://www.has-sante.fr/portail/jcms/c_2848077/fr/harvoni-sofosbuvir/ledipasvir-antiviral-a-action-directe
https://www.has-sante.fr/portail/jcms/c_2848077/fr/harvoni
2018
false
false
false
France
French
evaluation of the transparency committee
administration, oral
treatment outcome
drug combinations
benzimidazoles
benzimidazoles
fluorenes
fluorenes
antiviral agents
antiviral agents
hepatitis C, chronic
guidelines for drug use
insurance, health, reimbursement
ledipasvir
ledipasvir
Sofosbuvir
Sofosbuvir
ledipasvir, sofosbuvir drug combination
ledipasvir, sofosbuvir drug combination
sofosbuvir and ledipasvir
adolescent
uridine monophosphate
uridine monophosphate
uridine monophosphate

---
http://circulaire.legifrance.gouv.fr/index.php?action=afficherCirculaire&hit=1&r=42484
http://circulaire.legifrance.gouv.fr/pdf/2017/08/cir_42484.pdf
2017
false
false
false
France
French
legislation
insurance, health, reimbursement
hepatitis C, chronic
elbasvir-grazoprevir drug combination
dasabuvir
legislation, drug
antiviral agents
ritonavir
Product containing ombitasvir and paritaprevir and ritonavir in oral dose form (medicinal product form)
ombitasvir
paritaprevir
direct acting antivirals
daclatasvir
administration, oral
Simeprevir
sofosbuvir-velpatasvir drug combination
ledipasvir, sofosbuvir drug combination
Multidisciplinary care conference (procedure)
Interdisciplinary medical team conference (procedure)
dasabuvir
ombitasvir
paritaprevir
daclatasvir
benzofurans
drug combinations
imidazoles
quinoxalines
Sofosbuvir
carbamates
Heterocyclic Compounds, 4 or More Rings
benzimidazoles
fluorenes
uridine monophosphate
uridine monophosphate
sulfonamides
uracil
uracil
anilides
macrocyclic compounds

---
https://afef.asso.fr/wp-content/uploads/2018/06/VF-INTERACTIF-RECO-VHC-AFEF-v2103.pdf
http://www.infectiologie.com/UserFiles/File/medias/Recos/2015-juin-Recommandations-AFEF-Hepatite-C.pdf
2016
false
false
true
false
France
French
hepatitis C, chronic
practice guideline
severity of illness index
hepatitis C, chronic
antiviral agents
comorbidity
genotype
daclatasvir
ledipasvir
ribavirin
treatment outcome
drug resistance, viral
pregnancy
patient education as topic
liver cirrhosis
liver transplantation
recurrence
renal insufficiency
child
adolescent
drug users
hiv infections
acute disease
Acute hepatitis C
Simeprevir
Sofosbuvir
ledipasvir
ledipasvir, sofosbuvir drug combination
daclatasvir
imidazoles
benzimidazoles
fluorenes
uridine monophosphate
uridine monophosphate

---
http://www.has-sante.fr/portail/jcms/c_2728866/fr/reevaluation-des-antiviraux-d-action-directe-dans-le-traitement-de-l-hepatite-c
2016
false
false
false
France
French
guidelines for drug use
practice guideline
antiviral agents
hepatitis C, chronic
drug evaluation
Sofosbuvir
administration, oral
Simeprevir
direct acting antivirals
daclatasvir
ledipasvir
ledipasvir, sofosbuvir drug combination
drug therapy, combination
ritonavir
ombitasvir
paritaprevir
dasabuvir
drug resistance, viral
drug interactions
treatment outcome
daclatasvir
ombitasvir
paritaprevir
dasabuvir
benzimidazoles
fluorenes
uridine monophosphate
uridine monophosphate
imidazoles
anilides
carbamates
macrocyclic compounds
sulfonamides
uracil
uracil

---
http://www.has-sante.fr/portail/jcms/c_2633680/fr/antiviraux-d-action-directe
2016
false
false
false
France
French
evaluation of the transparency committee
adult
hepatitis C, chronic
drug therapy, combination
Sofosbuvir
antiviral agents
direct acting antivirals
daclatasvir
Simeprevir
ledipasvir, sofosbuvir drug combination
dasabuvir
drug combinations
ombitasvir
ritonavir
paritaprevir
fibrosis, liver
risk
has patient
hepacivirus
Infections
autoimmune diseases
hepatic fibrosis, nos
fibrosis
hepatitis C virus
human enterovirus 72
hepatitis C, chronic
business
liver cirrhosis
socialism
patients
chronic infectious disease
guideline
antiviral agents
chronic hepatitis, nos
health
case management
hepatitis c virus
hepatitis a virus
dasabuvir
ombitasvir
paritaprevir
daclatasvir
fibrosis
commerce
patients
guideline
benzimidazoles
fluorenes
uridine monophosphate
sulfonamides
uracil
uracil
anilides
carbamates
macrocyclic compounds
imidazoles

---
http://www.has-sante.fr/portail/jcms/c_2022100/fr/harvoni
http://www.has-sante.fr/portail/jcms/c_2022100/fr/harvoni-sofosbuvir/ledipasvir-association-fixe-dantiviraux-a-action-directe
2015
false
false
false
France
French
evaluation of the transparency committee
administration, oral
treatment outcome
drug combinations
benzimidazoles
benzimidazoles
fluorenes
fluorenes
antiviral agents
antiviral agents
hepatitis C, chronic
adult
guidelines for drug use
Hepatitis C virus genotype 1 (organism)
Hepatitis C virus genotype 3 (organism)
Hepatitis C virus genotype 4 (organism)
insurance, health, reimbursement
ledipasvir
ledipasvir
Sofosbuvir
Sofosbuvir
ledipasvir, sofosbuvir drug combination
ledipasvir, sofosbuvir drug combination
sofosbuvir and ledipasvir
uridine monophosphate
uridine monophosphate
uridine monophosphate

---
https://reptox.cnesst.gouv.qc.ca/pages/fiche-complete.aspx?no_produit=4770&nom=Acétamino-2+fluorène
Canada
toxicological data sheet
fluorene
fluorene
fluorenes

---
https://reptox.cnesst.gouv.qc.ca/pages/fiche-complete.aspx?no_produit=115824&nom=Fluorène
Canada
toxicological data sheet
fluorenes
fluorene
fluorene

---
https://www.ema.europa.eu/medicines/human/EPAR/Harvoni
2014
false
false
false
United Kingdom
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
drug combinations
benzimidazoles
benzimidazoles
fluorenes
fluorenes
antiviral agents
antiviral agents
adult
hepatitis C, chronic
administration, oral
tablets
NS-5 protein, hepatitis C virus
NS-5a protein, hepatitis C virus
NS-5b protein, hepatitis C virus
treatment outcome
product surveillance, postmarketing
aged
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
ledipasvir
ledipasvir
Sofosbuvir
Sofosbuvir
ledipasvir, sofosbuvir drug combination
ledipasvir, sofosbuvir drug combination
sofosbuvir and ledipasvir
viral nonstructural proteins
uridine monophosphate
uridine monophosphate
uridine monophosphate

---
https://reptox.cnesst.gouv.qc.ca/pages/fiche-complete.aspx?no_produit=1101385&nom=BENZO%28J%29FLUORANTHRENE
Canada
French
fluorenes
benzo(j)fluoranthene
toxicological data sheet

---
http://www.ineris.fr/substances/fr/substance/getDocument/2790
2006
toxicological data sheet
fluorene
fluorenes
fluorene

---
Nous contacter.
01/05/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.